The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Amrita Krishnan
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In the RedirecTT-1 trial, how did dual targeting of BCMA and GPRC5D impact response rates compared with either teclistamab or talquetamab monotherapy?
A
B
C
D
Video series
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Amrita Krishnan, City of Hope Comprehensive Cancer Center, Duarte, US, delivered a presentation on novel strategies using bispecific antibodies beyond B-cell maturation antigen (BCMA)-directed therapies.
Krishnan discussed alternative targets for bispecific antibodies on myeloma cells, including G-protein coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-homolog 5 (FcRH5), touching on a new development in dual-targeting trispecific antibodies (Figure 1). Krishnan presented clinical data from approved and investigational non-BCMA targeting agents, as well as highlighting the optimal sequencing in the myeloma treatment paradigm (Figure 2).
Figure 1. Mechanism of action of JNJ-79635322, a potential first-in-class trispecific antibody targeting BCMA, GPRC5D, and CD3
BCMA, B-cell maturation antigen; GPRC5D, G protein–coupled receptor family C group 5 member D; IFN-γ, interferon-gamma; IgG, immunoglobulin G; IL, interleukin; MM, multiple myeloma; TNF, tumor necrosis factor.
*Adapted from Pillarisetti, et al.1
Figure 2. Response rates with CAR T-cell and subsequent therapy after talquetamab in the MonumenTAL-1 trial*
BsAb, bispecific antibody; CAR, chimeric antigen receptor; CR, complete response; GPRC5D, G protein–coupled receptor, class C group 5 member D; IMiD, immunomodulatory agent; mAb, monoclonal antibody; ORR, overall response rate; PI, proteosome inhibitor; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
*Data from Sanchez.2
This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
